Nouveau Marché gets first IPO in three years

Immuno-Designed Molecules, the cancer treatment specialist, plans to test the Nouveau Marché in the first significant flotation for three years. UBS is leading the deal.

The float comes amid a difficult market for initial public offerings and weak support for the biotechnology sector.

WSJ Logo
Ray Dalio Sells Last Stake in Bridgewater, the Hedge Fund That Made Him a BillionaireExternal link

Ray Dalio Sells Last Stake in Bridgewater, the Hedge Fund That Made Him a Billionaire